140 related articles for article (PubMed ID: 37289413)
1. A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia.
Lin D; Pilon D; Morrison L; Shah A; Lafeuille MH; Lefebvre P; Benson C
Drugs Real World Outcomes; 2023 Sep; 10(3):471-480. PubMed ID: 37289413
[TBL] [Abstract][Full Text] [Related]
2. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia.
Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C
Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866
[TBL] [Abstract][Full Text] [Related]
4. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
[TBL] [Abstract][Full Text] [Related]
5. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States.
Patel C; Pilon D; Gupta D; Morrison L; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2022; 25(1):792-807. PubMed ID: 35635250
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
[TBL] [Abstract][Full Text] [Related]
8. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
Basu A; Benson C; Alphs L
J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
[TBL] [Abstract][Full Text] [Related]
9. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
[No Abstract] [Full Text] [Related]
10. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
11. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
[TBL] [Abstract][Full Text] [Related]
12. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.
Cai Q; Patel C; Kim E; Connolly N; Tunceli O; El Khoury AC
Adv Ther; 2019 Apr; 36(4):858-869. PubMed ID: 30848442
[TBL] [Abstract][Full Text] [Related]
14. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
Huang CY; Fang SC; Shao YJ
JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
[TBL] [Abstract][Full Text] [Related]
16. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
Kamstra R; Pilon D; Lefebvre P; Emond B; Joshi K
Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
[TBL] [Abstract][Full Text] [Related]
19. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
20. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
[Next] [New Search]
